TY - JOUR
T1 - Tegaserod accelerates orocecal transit in patients with constipation- predominant irritable bowel syndrome
AU - Prather, Charlene M.
AU - Camilleri, Michael
AU - Zinsmeister, Alan R.
AU - McKinzie, Sanna
AU - Thomforde, George
N1 - Funding Information:
Sponsored by Novartis Inc. and supported in part by National Institutes of Health (NIH) General Clinical Research Center grant RR00585 and NIH grants R01-DK54681 and K24 DK02638-01 (to M.C.).
PY - 2000
Y1 - 2000
N2 - Background and Aims: This study evaluated the effects of a partial 5- hydroxytryptamine (5-HT)4 agonist, tegaserod, on gastric small bowel and colonic transit in constipation-predominant irritable bowel syndrome (IBS). Methods: After a 1 week run-in period, 24 patients with constipation- predominant IBS were randomized to 1 week of tegaserod, 2 mg twice daily, or placebo treatment. Scintigraphic gastric emptying, small bowel transit, and colonic transit were determined before administration of study drug and after 1 week on the medication. Colonic transit was also measured using radiopaque markers and a single radiograph on day 5. Results: Gastric emptying was unaltered by tegaserod. Proximal colonic filling at 6 hours, a measure of orocecal transit, was accelerated by tegaserod (70.4% ± 1.3% [mean ± SEM] vs. placebo, 46.4 ± 1.9; P = 0.015). Proximal colonic emptying half-time and geometric center at 48 hours were also accelerated by tegaserod compared with baseline, but not compared with placebo. Mean colonic transit time was similar in both groups at baseline and after drug administration (tegaserod, 59.5 ± 2.1 hours; placebo, 62.1 ± 2.1 hours). Conclusions: Tegaserod accelerates orocecal transit, tends to accelerate coIonic transit, and deserves further study in patients with constipation-predominant IBS.
AB - Background and Aims: This study evaluated the effects of a partial 5- hydroxytryptamine (5-HT)4 agonist, tegaserod, on gastric small bowel and colonic transit in constipation-predominant irritable bowel syndrome (IBS). Methods: After a 1 week run-in period, 24 patients with constipation- predominant IBS were randomized to 1 week of tegaserod, 2 mg twice daily, or placebo treatment. Scintigraphic gastric emptying, small bowel transit, and colonic transit were determined before administration of study drug and after 1 week on the medication. Colonic transit was also measured using radiopaque markers and a single radiograph on day 5. Results: Gastric emptying was unaltered by tegaserod. Proximal colonic filling at 6 hours, a measure of orocecal transit, was accelerated by tegaserod (70.4% ± 1.3% [mean ± SEM] vs. placebo, 46.4 ± 1.9; P = 0.015). Proximal colonic emptying half-time and geometric center at 48 hours were also accelerated by tegaserod compared with baseline, but not compared with placebo. Mean colonic transit time was similar in both groups at baseline and after drug administration (tegaserod, 59.5 ± 2.1 hours; placebo, 62.1 ± 2.1 hours). Conclusions: Tegaserod accelerates orocecal transit, tends to accelerate coIonic transit, and deserves further study in patients with constipation-predominant IBS.
UR - http://www.scopus.com/inward/record.url?scp=0034089045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034089045&partnerID=8YFLogxK
U2 - 10.1016/S0016-5085(00)70251-4
DO - 10.1016/S0016-5085(00)70251-4
M3 - Article
C2 - 10702196
AN - SCOPUS:0034089045
SN - 0016-5085
VL - 118
SP - 463
EP - 468
JO - Gastroenterology
JF - Gastroenterology
IS - 3
ER -